Experienced in Chondrocalcinosis 2

Dr. Anca D. Askanase

Rheumatology
Trustees Of Columbia University In The City Of New York
161 Fort Washington Ave, 
New York, NY 
Offers Telehealth
Experienced in Chondrocalcinosis 2
Trustees Of Columbia University In The City Of New York
161 Fort Washington Ave, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Anca Askanase is a Rheumatologist in New York, New York. Dr. Askanase is rated as an Experienced provider by MediFind in the treatment of Chondrocalcinosis 2. Her top areas of expertise are Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Undifferentiated Connective Tissue Disease (UCTD), and Cutaneous Lupus Erythematosus (CLE).

Her clinical research consists of co-authoring 164 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Rheumatology
Licenses
Internal Medicine in NY
Hospital Affiliations
New York-Presbyterian Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VNS Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
161 Fort Washington Ave, New York, NY 10032
Other Locations
TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
622 W 168th St, New York, NY 10032

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Open-label Prospective Randomized Study to Determine the Efficacy and Safety of Two Dosing Regimens of ACTHar in the Treatment of Proliferative Lupus Nephritis.
Open-label Prospective Randomized Study to Determine the Efficacy and Safety of Two Dosing Regimens of ACTHar in the Treatment of Proliferative Lupus Nephritis.
Enrollment Status: Terminated
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drugs: CellCept, ACTHar Gel
Study Phase: Phase 4
Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID
Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID
Enrollment Status: Terminated
Publish Date: February 27, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101 in Systemic Lupus Erythematosus
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101 in Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: November 18, 2022
Intervention Type: Drug
Study Drug: JBT-101
Study Phase: Phase 2
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Enrollment Status: Completed
Publish Date: December 01, 2020
Intervention Type: Drug, Biological
Study Phase: Phase 2
View 5 Less Clinical Trials

164 Total Publications

The role of mTOR signaling pathway in systemic lupus erythematosus and systemic vasculitis.
The role of mTOR signaling pathway in systemic lupus erythematosus and systemic vasculitis.
Journal: Autoimmunity reviews
Published: July 29, 2025
Similar Doctors
Distinguished in Chondrocalcinosis 2
Dr. Stuart N. Novack
Rheumatology
Distinguished in Chondrocalcinosis 2
Dr. Stuart N. Novack
Rheumatology

Nuvance Health Medical Practice Ct Inc

761 Main Ave, 
Norwalk, CT 
 (35.0 miles away)
203-403-3490
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stuart Novack is a Rheumatologist in Norwalk, Connecticut. Dr. Novack is rated as an Advanced provider by MediFind in the treatment of Chondrocalcinosis 2. His top areas of expertise are Chondrocalcinosis 2, Calcium Pyrophosphate Arthritis, Rhizomelic Pseudopolyarthritis, and Polymyalgia Rheumatica.

Distinguished in Chondrocalcinosis 2
Dr. Maryanne C. Wysell
Rheumatology
Distinguished in Chondrocalcinosis 2
Dr. Maryanne C. Wysell
Rheumatology

Optum Medical Care PC

90 S Bedford Rd, 
Mount Kisco, NY 
 (27.2 miles away)
914-241-1050
Languages Spoken:
English
See accepted insurances

Maryanne Wysell is a Rheumatologist in Mount Kisco, New York. Dr. Wysell is rated as a Distinguished provider by MediFind in the treatment of Chondrocalcinosis 2. Her top areas of expertise are Rheumatoid Arthritis (RA), Psoriatic Arthritis, Muscle Spasms, and Fibromyalgia.

Advanced in Chondrocalcinosis 2
Dr. Wadie Toma
Rheumatology
Advanced in Chondrocalcinosis 2
Dr. Wadie Toma
Rheumatology

The Radiology Group Of New Jersey LLC

3840 Park Ave, Suite 102, 
Edison, NJ 
 (29.9 miles away)
732-869-1002
Experience:
44+ years
Languages Spoken:
English
See accepted insurances

Wadie Toma is a Rheumatologist in Edison, New Jersey. Dr. Toma has been practicing medicine for over 44 years and is rated as a Distinguished provider by MediFind in the treatment of Chondrocalcinosis 2. His top areas of expertise are Rheumatoid Arthritis (RA), Fibromyalgia, Psoriasis, and Gout.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Askanase's expertise for a condition
ConditionClose
View All 42 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile